NEW YORK (GenomeWeb News) – Pacific Biometrics said today that it has been awarded two contracts worth a total of $1.6 million from an unnamed company to provide clinical services for use in rheumatoid arthritis drug development programs.
The Seattle-based firm said the contracts are part of a series of four contracts related to a global development program. PBI will offer testing for a panel of inflammatory, metabolic, cardiovascular, and musculoskeletal biomarkers to support its partner’s phase III clinical program.
PBI CEO Ron Helm said the agreements should “have a meaningful impact” on the company’s financials in 2009, 2010, and in 2011.
Helm also said that the drug in question “may have applicability to a broader range of inflammatory diseases” beyond rheumatoid arthritis.
Further financial terms of the agreements were not released.